Pinealon Peptide UK: EDR Evidence in the Peptides UK Market
Pinealon Peptide UK: EDR Evidence in the Peptides UK Market
Pinealon is the name commonly used for the synthetic tripeptide Glu-Asp-Arg, abbreviated EDR. It belongs to a group of very short peptides developed within the Russian peptide-bioregulator research tradition. Laboratory studies have examined Pinealon in neuronal oxidative stress, hypoxia, dendritic-spine loss, DNA interactions, serotonin-related gene expression and cellular ageing. More recent research has also used human fibroblast-derived induced neurons. These studies create an interesting experimental hypothesis, but they do not establish Pinealon as an approved treatment for memory loss, dementia, stroke, sleep disturbance, depression, traumatic brain injury or biological ageing.
Direct Answer
Pinealon is a synthetic tripeptide composed of L-glutamic acid, L-aspartic acid and L-arginine.
Its sequence is Glu-Asp-Arg, abbreviated EDR in single-letter amino-acid notation.
The free peptide has the molecular formula C15H26N6O8 and an approximate average molecular weight of 418.4 g/mol.
It is a linear peptide with a free N-terminal amino group and a free C-terminal carboxylic-acid group. It contains no cysteine residues, disulphide bonds, fatty-acid attachments or glycosylation.
Laboratory studies report changes in reactive oxygen species, cell survival, dendritic structures and selected gene-expression measurements.
Fluorescence-labelled peptide experiments also reported entry into cultured HeLa cells and their nuclei. These findings do not demonstrate that unlabelled Pinealon crosses the human blood–brain barrier after oral, nasal or injectable exposure.
Small human reports describe cognitive, psychoemotional or biological-age measurements, but the evidence is not comparable with a large, independently replicated, randomised and placebo-controlled neurological trial.
No current UK marketing authorisation for a Pinealon medicinal product was identified in the official sources reviewed.
Pinealon Peptide Key Points
The central chemical, scientific and regulatory facts for readers assessing Pinealon in the Peptides UK market.
What Is Pinealon Peptide?
Pinealon is one of the smallest peptides promoted within the peptide-bioregulator category.
A peptide is formed when amino acids are joined through peptide bonds.
Pinealon contains only three residues, making it a tripeptide rather than a larger peptide hormone or protein.
Its first residue is glutamic acid, its middle residue is aspartic acid and its final residue is arginine.
The sequence order is important. Glu-Asp-Arg is not interchangeable with Glu-Arg-Asp, Asp-Glu-Arg or another tripeptide containing the same three residues.
Pinealon is frequently described as a “cytogen”, “bioregulator”, “geroprotector” or “brain peptide”.
These descriptions reflect the research tradition in which it was developed. They are not recognised UK medicine classifications and do not independently establish efficacy.
Pinealon Names and Terminology
The sequence name is more scientifically informative than many commercial descriptions.
| Name | Meaning | Important Distinction |
|---|---|---|
| Pinealon | Common development and commercial name | Does not prove selective action on the pineal gland |
| EDR peptide | Single-letter abbreviation for Glu-Asp-Arg | Most precise short sequence description |
| Glu-Asp-Arg | Three-letter amino-acid sequence | Sequence order must be preserved |
| Glutamyl-aspartyl-arginine | Extended chemical sequence name | May appear in analytical catalogues |
| Peptide bioregulator | Research-category description | Not a marketing authorisation or recognised therapeutic class |
| Cytogen | Commercial terminology used for certain synthetic short peptides | Should not be confused with cytogenetics |
| Epitalon | Ala-Glu-Asp-Gly tetrapeptide | A completely different molecule |
| Cortexin | A complex mixture of animal-brain-derived polypeptides | Not identical to purified synthetic EDR |
Pinealon is not Epitalon
Pinealon has three residues and the sequence EDR. Epitalon has four residues and the sequence AEDG. Claims, studies and analytical certificates for one cannot be transferred to the other.
Where Did Pinealon Research Originate?
The peptide was developed within work on short sequences associated with organ-derived polypeptide complexes.
Russian researchers investigated extracts obtained from organs and tissues, then attempted to identify shorter sequences that might reproduce selected biological effects.
Modern laboratory literature describes EDR as a sequence associated with a cerebral-cortex polypeptide complex.
This differs from AEDG, or Epitalon, which is associated with pineal-gland peptide research.
Cortexin itself is a complex mixture rather than a single defined tripeptide.
Synthetic Pinealon is therefore more chemically defined than an animal-tissue extract, but that does not prove it reproduces every action attributed to the original complex.
The commercial name can create a false pineal-gland association
Reliable interpretation should follow the actual EDR sequence and the experimental system rather than inferring a melatonin or pineal action from the name Pinealon.
Pinealon Molecular and Scientific Profile
Correct identity requires confirmation of sequence order, stereochemistry, terminal groups and counterions.
Glu-Asp-Arg Tripeptide
A linear peptide containing three standard L-amino-acid residues.
It has no disulphide bridge, lipid attachment, carbohydrate group or C-terminal amide.
Proposed Neuroregulatory Peptide
Studied in models involving oxidative stress, neuronal morphology, hypoxia and gene-expression regulation.
No single clinically validated human receptor or molecular target has been established.
| Common name | Pinealon |
|---|---|
| Sequence name | Glu-Asp-Arg |
| Single-letter abbreviation | EDR |
| Peptide length | Three amino-acid residues |
| Molecular formula | C15H26N6O8 |
| Approximate molecular weight | 418.4 g/mol |
| N-terminus | Free amino group on glutamic acid |
| C-terminus | Free carboxylic-acid group on arginine |
| Disulphide bonds | None |
| Approximate physiological character | Small, highly polar and ionisable |
| Validated human receptor | None identified |
| UK marketing authorisation | None identified |
Pinealon Amino-Acid Sequence
Three residues may appear simple, but sequence direction and terminal chemistry remain essential.
“H” indicates the ordinary free N-terminus.
“OH” indicates that the C-terminal arginine is present as a free carboxylic acid rather than an amide.
The glutamic-acid and aspartic-acid side chains are acidic.
Arginine contains a strongly basic guanidinium group.
At physiological pH, Pinealon is expected to exist as a charged and highly polar molecule.
Same formula does not prove the same sequence
Glu-Asp-Arg, Glu-Arg-Asp and Asp-Glu-Arg contain the same amino acids and can have the same intact molecular mass. Tandem mass spectrometry or another sequence-specific method is needed to distinguish them.
Pinealon Chemical Properties and Stability
The absence of cysteine makes its chemistry simpler than many research peptides, but degradation can still occur.
N-Terminal Cyclisation
N-terminal glutamic acid can form pyroglutamate under some manufacturing or storage conditions.
Cyclisation removes water and creates a related molecule with different mass, charge and terminal structure.
Aspartic-Acid Isomerisation
Aspartic-acid-containing peptides can form aspartimide or isoaspartate-related impurities under unsuitable conditions.
These variants may share a very similar or identical mass while differing in peptide-bond structure.
Hydrolysis
Peptide bonds may break during prolonged exposure to unsuitable pH, heat or moisture.
Epimerisation
Manufacturing can produce small quantities of D-amino-acid or epimerised forms.
Epimers have the same formula and molecular mass as the intended all-L peptide.
Counterions
Synthetic peptides are often isolated as trifluoroacetate, acetate or another salt.
Counterions and water add to vial weight, meaning total powder mass is not the same as net Pinealon content.
Can Pinealon Enter Cells and Cell Nuclei?
Fluorescence-labelled cell research suggests uptake, but the experiment does not establish human brain delivery.
Researchers attached fluorescent labels to Pinealon and several other short peptides.
Fluorescence was observed within the cytoplasm, nucleus and nucleolus of cultured HeLa cells.
This finding supports the possibility that short peptides can enter certain cultured cells.
A fluorescent label changes molecular size, hydrophobicity and charge and may influence uptake.
HeLa cells are an immortalised cervical-cancer cell line rather than human neurons or blood–brain-barrier cells.
The experiment does not establish absorption from the intestine, survival in blood, entry into the human brain or concentration at neuronal targets.
Cell penetration is not blood–brain-barrier penetration
A peptide entering a cultured cell under controlled laboratory conditions does not prove that an oral, nasal or injected product reaches the human brain intact.
Pinealon and DNA-Interaction Research
Biophysical studies propose sequence-dependent interactions with short DNA structures.
Fluorescence-quenching experiments reported interactions between Pinealon and selected deoxyribooligonucleotides.
Nuclear magnetic resonance, viscosity measurements and molecular-dynamics simulations have also been used to examine EDR–DNA interactions.
The research suggests that hydrogen bonding, electrostatic forces and metal ions may affect peptide association with nucleotide sequences.
This creates a hypothesis that EDR might influence chromatin or gene expression through direct nucleic-acid interactions.
The experiments do not establish which genomic sites are occupied in living human neurons.
They also do not demonstrate clinically meaningful gene regulation after ordinary human exposure.
DNA binding is not proof of safe epigenetic “reprogramming”
Many charged molecules interact with nucleic acids in vitro. Therapeutic relevance requires validated target engagement, concentration, selectivity, reproducibility and safety in living organisms.
How Is Pinealon Proposed to Work?
Several overlapping mechanisms have been proposed, but none has been confirmed as a complete human pharmacological pathway.
Oxidative-Stress Modulation
Pinealon reduced reactive oxygen species in several stressed cell systems.
Researchers proposed activation or preservation of intracellular antioxidant systems rather than simple chemical scavenging alone.
MAPK and ERK Signalling
Cell studies reported altered timing of ERK1/2 activation.
MAPK pathways participate in cell survival, differentiation, stress responses and proliferation.
Apoptosis-Related Proteins
Experimental work has examined caspase-3, p53 and other proteins associated with programmed cell death.
Gene Expression
EDR has been linked experimentally to expression of antioxidant enzymes, NMDA-receptor subunits, serotonin-related enzymes and other proteins.
Neuronal Morphology
Cultured-neuron studies reported changes in dendritic processes and spine preservation.
Pinealon and Oxidative-Stress Research
One of the most frequently cited studies examined reactive oxygen species and cell viability.
Pinealon was tested in cultured cerebellar granule cells, neutrophils and PC12 cells.
Oxidative stress was induced through different experimental pathways.
The study reported a concentration-related restriction of reactive oxygen species and reduced necrotic cell death.
ERK1/2 activation and cell-cycle measurements also changed.
The authors proposed that antioxidant effects occurred at lower concentrations while cell-cycle effects continued at higher concentrations.
These results do not demonstrate antioxidant treatment of a human neurological disease.
“Antioxidant” is not a complete safety description
A small human study later reported pro-oxidant chemiluminescence findings during research involving Pinealon and Vesugen. Effects may depend on concentration, tissue, formulation and experimental conditions.
The 2024 Human Induced-Neuron Study
This study used neurons created from skin fibroblasts donated by older adults, but it remained an in-vitro experiment.
Researchers converted dermal fibroblasts from elderly donors into induced cortical neurons.
The cells were exposed to EDR, KED or AEDG peptides.
All three peptides increased aspects of dendritic-tree arborisation, including the number of primary processes and total dendrite length.
EDR produced a near-significant reduction in the oxidative-DNA-damage marker 8-OHdG, reported with a p value slightly above the conventional 0.05 threshold.
The tripeptides did not improve every marker.
EDR and KED did not produce significant changes in mitochondrial activity, lysosomal activity or p16 expression in the reported model.
The findings support further research into neuronal morphology rather than clinical use.
Human-derived cells are not a human clinical trial
The neurons were grown and treated in a laboratory dish. The study did not measure memory, dementia progression, mood, sleep, daily function or adverse events in a person.
Pinealon and Dendritic-Spine Research
Dendritic spines are small neuronal structures involved in synaptic communication and plasticity.
Experimental models of Alzheimer’s and Huntington’s disease can show loss or alteration of dendritic spines.
EDR and other tripeptides were tested in cultured neurons obtained from relevant mouse models.
Researchers reported preservation or restoration of selected spine measurements.
Dendritic morphology is a useful mechanistic endpoint, but it is not equivalent to restored cognition.
Mouse neurons carrying disease-associated genetic changes do not reproduce the complete biology of sporadic human dementia.
No large clinical trial has demonstrated that Pinealon preserves human synapses or slows neurodegenerative disease.
Pinealon and Hypoxia Research
Animal studies have examined oxygen deprivation during development and in older animals.
Prenatal Hypoxia
Rat research investigated whether short peptides altered neuronal resistance after oxygen deprivation during pregnancy.
Pinealon produced favourable findings in behavioural and neuronal-stress measurements within selected models.
Prenatal Hyperhomocysteinaemia
Another rat study examined offspring exposed to elevated maternal homocysteine.
Pinealon reduced reactive-oxygen-species accumulation in cultured cerebellar neurons obtained from the offspring and was associated with improved cell survival.
Acute Hypoxia and Ischaemia
Studies in older rats examined carotid-artery occlusion or hypoxic exposure and measured behaviour, inflammatory cytokines and caspase-3 activity.
These are preclinical injury models and do not establish treatment of stroke, vascular dementia or neonatal brain injury.
Suspected stroke requires emergency treatment
Pinealon research must not be used to delay emergency assessment, brain imaging, thrombolysis, thrombectomy or other evidence-based stroke care.
Pinealon, Diabetes and Learning Research
A 2020 rat study examined retained spatial learning and hippocampal NMDA-receptor gene expression.
Rats were trained in a Morris water maze before experimental diabetes was induced with streptozotocin.
Pinealon was examined at several experimental exposures.
The middle tested exposure produced the strongest preservation of the previously acquired task.
Expression of Grin1, Grin2a, Grin2b and Grin2d receptor-subunit genes was also assessed in the hippocampus.
The findings were dose dependent rather than showing that more peptide always produced a stronger result.
Streptozotocin-induced diabetes in rats does not establish effectiveness for human diabetic cognitive impairment or diabetic neuropathy.
The study examined retained learning in rats
It did not establish improved blood-glucose control, prevention of human dementia or restoration of memory in people with diabetes.
Pinealon and Serotonin-Related Research
Cell-culture findings are sometimes overstated as proof of mood or antidepressant effects.
EDR and KED were tested in ageing cultures of rat cerebral-cortex cells.
The researchers reported increased serotonin expression.
Molecular docking was also used to propose interaction with a sequence associated with the gene encoding tryptophan hydroxylase.
Serotonin expression in a cultured rat-cell system is not equivalent to a measured change in human brain serotonin.
No adequate randomised clinical trial has established Pinealon as a treatment for depression, anxiety or another psychiatric condition.
Gene-expression research does not justify antidepressant claims
Mood disorders involve distributed neural systems, environment, psychology, inflammation, hormones and multiple neurotransmitters. One cell-culture marker cannot establish a clinical treatment.
Pinealon and Alzheimer’s Disease Research
Published discussion is mainly mechanistic and preclinical.
A 2020 review proposed that EDR could influence proteins and pathways relevant to Alzheimer’s disease.
Discussed targets included ERK1/2, caspase-3, p53, antioxidant enzymes, transcription factors and serotonin-related proteins.
Some supporting findings came from cultured neurons and molecular modelling.
The review did not report a large randomised trial in people with Alzheimer’s disease.
No evidence establishes reduced amyloid burden, reduced tau pathology, slower clinical progression or preserved independence in diagnosed patients.
Pinealon should therefore not be described as an Alzheimer’s medicine, dementia cure or clinically proven neuroprotective treatment.
Pinealon and Huntington’s Disease Research
Dendritic-spine findings in cultured mouse neurons have not established treatment of inherited Huntington’s disease.
Huntington’s disease results from an expanded CAG repeat in the HTT gene.
Cultured-neuron models can be used to study synaptic structure and disease-associated stress.
EDR was reported to influence dendritic-spine loss in a mouse-derived model.
The experiment did not show reduced mutant huntingtin, delayed clinical onset or improved survival in patients.
No authorised Huntington’s indication exists for Pinealon.
Pinealon, Sleep and Melatonin Claims
The commercial sleep narrative is substantially stronger than the direct evidence.
Pinealon is frequently promoted as a pineal-gland peptide that restores melatonin or corrects circadian rhythm.
The EDR sequence is more closely associated in the research literature with a cerebral-cortex polypeptide complex than with the pineal-gland AEDG sequence.
One organotypic pineal-gland study included EDR among several short peptides.
EDR did not produce the same reported proliferative or secretory-marker effect as AEDG in that experiment.
No robust polysomnography trial has shown that Pinealon increases total sleep time, slow-wave sleep or REM sleep.
No adequate human trial has established normalisation of melatonin rhythms, treatment of insomnia or correction of jet lag.
Pinealon’s name should not be treated as a mechanism
Claims that it “targets the pineal gland” or “restores melatonin” require direct pharmacokinetic, endocrine and sleep-study evidence that has not been established.
Pinealon, Irisin, Telomeres and Longevity Claims
Gene-expression hypotheses do not demonstrate extension of human lifespan.
EDR has been discussed in relation to expression of FNDC5, the precursor associated with irisin.
Irisin is investigated in exercise, metabolism and ageing biology.
Publications have proposed that short peptides might influence lifespan-related pathways through irisin expression.
Pinealon has not been shown in a large controlled human trial to extend telomeres, reduce mortality or increase healthy lifespan.
Changes in a gene-expression marker cannot be converted directly into a lifespan prediction.
“Geroprotector” is therefore best understood as a research description rather than a proven clinical outcome.
What Human Evidence Exists for Pinealon?
The human evidence is limited, regionally concentrated and often lacks sufficient methodological detail.
Published abstracts describe Pinealon use in older adults, people with organic brain syndromes and occupational groups exposed to chronic stress.
Some reviews also describe use alongside standard treatment in people with consequences of traumatic brain injury.
Important limitations recur throughout the literature:
- small participant numbers;
- Russian-language publications with limited accessible methodology;
- unclear randomisation or allocation concealment;
- limited placebo control;
- combined peptide interventions;
- subjective or composite endpoints;
- short follow-up;
- limited independent replication;
- absence of modern trial-registration records; and
- no successful phase-three development programme.
These studies are relevant to the history of Pinealon research but cannot support broad claims of proven cognitive enhancement.
The Thirty-Two-Person Organic Brain Syndrome Study
This study is often cited as human evidence but assessed a small and clinically mixed population.
The publication included 32 people aged between 41 and 83 years.
Participants had multiple chronic conditions and an organic brain syndrome described as being in remission.
Pinealon and Vesugen were assessed in relation to biological-age, metabolic and central-nervous-system measurements.
The abstract reported favourable changes in selected measurements.
It also reported pro-oxidant chemiluminescence activity and a decrease in circulating CD34-positive haematopoietic-cell markers.
The abstract does not provide a clean, independently replicated, placebo-controlled estimate for Pinealon monotherapy.
The study does not prove general anti-ageing efficacy
Thirty-two heterogeneous participants and composite biological-age indicators cannot establish reduced dementia incidence, improved lifespan or safety in healthy adults.
Pinealon in Occupational-Stress Research
Studies involving professional drivers are frequently presented without explaining the intervention design.
One publication examined 150 male lorry drivers and 150 male metal craftsmen.
The research focused on occupational stress, psychological adaptation and borderline mental-health symptoms.
The authors reported improved psychoemotional indices after bioregulatory-peptide interventions.
The best reported effect involved a combination of Pinealon and Vesugen selected according to occupational exposures.
This makes it impossible to assign the outcome confidently to Pinealon alone.
Occupational questionnaire changes do not establish treatment of depression, attention-deficit disorder, dementia or sleep deprivation.
Combination findings are not Pinealon monotherapy findings
A study in which two peptides are used together cannot determine the independent contribution, interaction or optimal safety profile of either component.
Pinealon Evidence at a Glance
Chemical identity is well defined, while clinical effectiveness remains uncertain.
| Research Question | Evidence Type | Current Finding | Main Limitation |
|---|---|---|---|
| Is Pinealon a defined peptide? | PubChem and ChEBI chemical records | Yes, Glu-Asp-Arg | Commercial batches still require sequence testing |
| Can labelled Pinealon enter cultured cells? | Fluorescence-labelled HeLa-cell study | Cell and nuclear fluorescence reported | Labelled cancer cells, not human brain delivery |
| Can EDR interact with DNA in vitro? | Spectroscopy, NMR and molecular modelling | Interactions with selected oligonucleotides reported | No validated genomic target engagement in people |
| Does it reduce oxidative stress? | Cell-culture studies | Reduced ROS and necrotic death reported | Effects depend on cell model and concentration |
| Does it improve human-derived neuronal morphology? | 2024 induced-neuron experiment | Greater dendritic arborisation reported | In vitro rather than a clinical trial |
| Does it improve mitochondrial activity? | 2024 induced-neuron experiment | No significant EDR improvement reported | One laboratory model |
| Does it protect neurons from hypoxia? | Rat and cell studies | Favourable stress-response findings | No established human stroke or hypoxia treatment |
| Does it preserve learning in diabetes? | Streptozotocin-treated rat study | Dose-dependent retention signal reported | Animal model rather than human diabetes |
| Does it increase serotonin? | Ageing rat cortical-cell culture | Expression changes reported | No human mood-treatment evidence |
| Does it treat Alzheimer’s disease? | Reviews, cell culture and mouse-derived neurons | Not established | No clinical disease-modification trial |
| Does it improve sleep? | Direct controlled human sleep evidence | Not established | No robust polysomnography or melatonin trial |
| Does it extend lifespan? | Direct human longevity evidence | Not established | Gene-expression hypotheses are not lifespan outcomes |
| Do human studies show cognitive benefit? | Small regional studies and reviews | Preliminary favourable reports | Small, combined and incompletely reported interventions |
| Is it an authorised UK medicine? | Official regulatory-source review | No marketing authorisation identified | Online “research” presentation can obscure medicinal claims |
Important Pinealon Research Limitations
The evidence base is narrower than commercial descriptions commonly imply.
- No successful phase-three Pinealon programme was identified.
- No current UK marketing authorisation was identified.
- No large independent dementia trial was identified.
- No robust healthy-volunteer cognitive-enhancement trial was identified.
- No validated human pharmacokinetic profile was identified.
- Oral bioavailability has not been established adequately.
- Human blood–brain-barrier penetration has not been demonstrated.
- Fluorescence-labelled cell uptake may not represent unlabelled peptide.
- HeLa cells are not human neurons.
- DNA interactions were studied under laboratory conditions.
- No complete human genomic target map exists.
- No single validated receptor has been identified.
- Many publications originate from closely connected research groups.
- Independent replication is limited.
- Several relevant papers are available only in Russian or as English abstracts.
- Important methodological details are difficult to evaluate.
- Many studies are cellular or animal experiments.
- Animal prenatal-hypoxia models do not establish adult human treatment.
- Streptozotocin-treated rats do not reproduce every form of human diabetes.
- Dendritic-spine preservation does not establish cognitive recovery.
- Oxidative-stress markers are surrogate endpoints.
- Serotonin-expression findings do not establish antidepressant efficacy.
- Human studies used small and heterogeneous populations.
- Some human findings involved Pinealon and Vesugen together.
- Combination interventions prevent attribution to Pinealon alone.
- No adequate sleep-architecture study was identified.
- No robust melatonin-secretion study was identified.
- No human telomere or lifespan benefit was established.
- No long-term cancer-safety programme was identified.
- No adequate pregnancy-safety programme was identified.
- No paediatric efficacy programme was identified.
- Online products may contain sequence isomers with the same mass.
- Terminal modifications may be undeclared.
- A high HPLC area percentage does not establish clinical quality.
Pinealon Safety and Adverse-Event Evidence
Small size and use of ordinary amino acids do not replace a formal safety programme.
Short-Term Human Evidence
Small reports do not describe a consistent pattern of severe Pinealon-attributable adverse effects.
These studies are too small to detect uncommon or delayed events.
Pro-Oxidant Finding
The 32-person study involving Pinealon and Vesugen reported pro-oxidant activity through chemiluminescence measurements.
This complicates broad claims that Pinealon is always an antioxidant.
Haematopoietic Marker
The same abstract reported a reduction in circulating CD34-positive haematopoietic-cell markers.
The clinical significance and individual contribution of Pinealon were not established.
Cell-Cycle Effects
Laboratory research reported cell-cycle modulation at concentrations above those associated with saturated antioxidant effects.
Cell-cycle modification requires careful interpretation because its consequences may differ between healthy, senescent and malignant cells.
Neurological Effects
A compound intended to alter neuronal signalling cannot be assumed free from mood, sleep, sensory or cognitive adverse effects.
Long-Term Uncertainty
No large long-term programme has characterised malignancy, immune, cardiovascular, neurological or reproductive risks.
Absence of adverse-event reports is not proof of safety
Sparse human exposure, incomplete reporting and unregulated products make it difficult to determine true adverse-event frequency.
Research-Market Pinealon Quality Risks
A tripeptide is easier to synthesise than many larger peptides but still requires meaningful identity and purity controls.
- Incorrect peptide entirely
- Glu-Arg-Asp sequence isomer
- Asp-Glu-Arg sequence isomer
- Reversed amino-acid order
- Missing one amino-acid residue
- Free amino-acid contamination
- D-amino-acid or epimerised impurities
- N-terminal pyroglutamate formation
- Unexpected N-terminal acetylation
- Unexpected C-terminal amidation
- Aspartimide-related impurity
- Isoaspartate formation
- Peptide-bond hydrolysis
- Incorrect net peptide quantity
- Excess water
- Residual trifluoroacetate
- Undeclared acetate or other counterions
- Residual coupling reagents
- Residual organic solvents
- Elemental contamination
- Incorrect pH
- Microbial contamination
- Unverified bacterial-endotoxin control
- Unverified sterile quality
- Visible or subvisible particles
- Incorrect storage or warm transport
- Certificate unrelated to the supplied batch
- Raw-material certificate presented as finished-vial evidence
How Pinealon Research Material Should Be Analytically Tested
Intact mass alone is especially inadequate because several sequence isomers can have exactly the same formula.
High-Resolution Mass Spectrometry
The observed molecular mass should support the complete free EDR tripeptide and exclude major terminal modifications.
Tandem Mass Spectrometry
Fragment ions should confirm Glu followed by Asp followed by Arg rather than another sequence isomer.
Chiral Amino-Acid Analysis
Testing should establish that the intended L-amino acids are present and quantify epimerised material.
N- and C-Terminal Confirmation
The free amino terminus and free C-terminal acid should be distinguished from acetylated, cyclised or amidated variants.
Orthogonal Chromatography
Suitable chromatography should assess free amino acids, deletion sequences and related short-peptide impurities.
Net Peptide Assay
Active EDR content should be measured independently of water, counterions and residual salts.
Pyroglutamate and Isoaspartate Testing
Stability methods should detect N-terminal cyclisation and aspartic-acid-related structural variants.
Microbiological and Particle Testing
Any finished sterile medicine would require validated endotoxin, sterility and particulate controls.
What Meaningful Pinealon Documentation Should Include
- Identity as Glu-Asp-Arg
- Complete sequence order
- Observed intact molecular mass
- Tandem-MS fragment evidence
- L-amino-acid stereochemistry
- Free N-terminal identity
- Free C-terminal acid identity
- Pyroglutamate impurity result
- Aspartimide or isoaspartate assessment
- Net peptide-content assay
- Chromatographic purity
- Free amino-acid results
- Deletion-sequence results
- Named and unknown impurities
- Counterion identification
- Trifluoroacetate or acetate quantity
- Water-content result
- Residual-solvent results
- Residual synthesis-reagent results
- Elemental-impurity assessment where relevant
- pH and appearance
- Bacterial-endotoxin result
- Sterility result for a finished injectable medicine
- Visible and subvisible particle results
- Batch-specific stability evidence
- Container-closure compatibility
- Testing-laboratory identity
- Analytical methods and acceptance criteria
- A clear statement identifying tests not performed
Why “99% HPLC” Is Not Enough
HPLC area purity does not prove that the main peak contains Glu-Asp-Arg in the correct order.
Sequence isomers can possess the same molecular formula and intact mass.
HPLC also does not establish stereochemistry, terminal structure, net peptide quantity, endotoxin control or sterility.
A certificate for raw powder does not demonstrate clinical equivalence to material used in a published study.
Pinealon Regulation in the Peptides UK Market
Regulatory information checked on 22 July 2026.
No UK Marketing Authorisation Identified
No current UK marketing authorisation for a medicinal product containing Pinealon or Glu-Asp-Arg was identified in the official MHRA sources reviewed.
Pinealon should not be presented as an approved UK treatment for dementia, cognitive impairment, traumatic brain injury, stroke, anxiety, depression, insomnia, diabetes or biological ageing.
Publication of small human studies outside the UK does not create UK marketing authorisation.
Medicinal-Product Classification
The MHRA can classify a product as medicinal where it is presented as preventing or treating disease.
A product can also be medicinal where it is intended to restore, correct or modify physiological functions through pharmacological, immunological or metabolic action.
Claims involving dementia treatment, neuronal regeneration, stroke recovery, sleep correction or cognitive enhancement may therefore be relevant to medicinal classification.
“Research Use Only” Wording
A research disclaimer does not determine legal status by itself.
The MHRA may consider product names, claims, imagery, testimonials, administration material, websites, social media and intended consumer use.
Advertising Restrictions
Regulation 279 of the Human Medicines Regulations restricts advertising medicinal products without the required authorisation, registration or certificate.
This section provides general regulatory education and does not constitute legal advice.
Pinealon and Competitive Sport
Pinealon was not identified by name on the reviewed 2026 World Anti-Doping Agency Prohibited List.
The WADA S0 category prohibits pharmacologically active substances that are not addressed elsewhere and lack current approval by a governmental regulatory health authority for human therapeutic use.
Pinealon has no identified UK marketing authorisation and is promoted as pharmacologically active.
It is therefore reasonable to consider S0 potentially relevant, although this is an application of the general rule rather than a Pinealon-specific WADA listing.
Athletes should obtain a current product-specific determination from UK Anti-Doping, Global DRO or the relevant international federation.
Not named does not mean permitted
WADA’s S0 category exists partly to cover experimental and non-approved pharmacologically active substances before each substance is listed individually.
Pinealon Research in the Peptides UK Market
Online promotion frequently converts preliminary cell research into broad claims about cognition, sleep and longevity.
Pinealon appears in Peptides UK catalogues as lyophilised powder, oral-style capsules, nasal products and injectable-style research vials.
Common claims include improved memory, deeper sleep, higher serotonin, restored melatonin, protection from dementia, increased neurogenesis and reversal of brain ageing.
Many listings cite cell or animal studies without explaining the experimental system.
Others cite human studies involving Vesugen or standard therapy without identifying the combined design.
Some descriptions incorrectly call Pinealon a pineal-gland extract or confuse it with Epitalon.
Claims that a product crosses the blood–brain barrier are often based on labelled cultured-cell experiments rather than human pharmacokinetic evidence.
No clinical result can authenticate an online product without batch-specific analytical testing.
Small peptide does not mean simple clinical evidence
The EDR structure is chemically straightforward, but absorption, stability, brain exposure, target engagement and meaningful human outcomes remain unresolved.
Common Pinealon Peptide Claims Examined
Commercial descriptions frequently present preclinical findings as established human benefits.
“Pinealon is a pineal-gland peptide.”
EDR is associated in the research literature with cerebral-cortex peptide complexes.
AEDG, or Epitalon, is the separate sequence more closely associated with pineal-gland research.
“Pinealon and Epitalon are the same.”
Pinealon is EDR.
Epitalon is AEDG and contains a different number and order of amino acids.
“It crosses the human blood–brain barrier.”
Labelled-peptide uptake was reported in cultured HeLa cells.
Direct human blood–brain-barrier penetration has not been established.
“Pinealon directly reprogrammes DNA.”
In-vitro DNA and oligonucleotide interactions have been reported.
Safe, selective and clinically meaningful human genomic reprogramming has not been demonstrated.
“It prevents Alzheimer’s disease.”
Laboratory studies examined oxidative stress and dendritic structures.
No clinical prevention trial has demonstrated reduced Alzheimer’s incidence.
“It reverses dementia.”
No large randomised trial established improved cognition, function or disease progression in diagnosed dementia.
“It regenerates human brain cells.”
Cultured-neuron studies reported changes in dendrites and cellular markers.
Formation of new functional neurons in the human brain has not been demonstrated clinically.
“It increases serotonin and treats depression.”
Serotonin-expression changes were reported in ageing rat cortical-cell cultures.
No adequate antidepressant trial was identified.
“It restores melatonin and sleep.”
Robust human melatonin and polysomnography evidence was not identified.
The claim appears partly driven by the commercial name.
“It is always an antioxidant.”
Cell experiments reported lower reactive oxygen species.
A small human study involving Pinealon and Vesugen also reported pro-oxidant chemiluminescence activity.
“It extends human lifespan.”
No controlled human survival study established longer life from Pinealon.
Irisin and gene-expression hypotheses are not mortality outcomes.
“Human trials prove cognitive enhancement.”
Human reports were small and often used combined treatments.
No large independently replicated healthy-person cognition trial was identified.
“It is safe because it contains natural amino acids.”
Ordinary amino acids can form a pharmacologically active sequence.
Long-term exposure and product impurities remain separate safety questions.
“A 99% HPLC result proves genuine Pinealon.”
Sequence isomers may have the same formula and intact mass.
Sequence-specific, stereochemical and terminal testing remains necessary.
Pinealon Compared With Related Neuroactive Peptides
Shared brain or ageing claims do not mean that the molecules have the same structure or evidence.
| Compound | Basic Identity | Main Research Context | Important Distinction |
|---|---|---|---|
| Pinealon | Glu-Asp-Arg tripeptide | Oxidative stress, neuronal morphology and gene regulation | No established clinical neurological indication |
| Epitalon | Ala-Glu-Asp-Gly tetrapeptide | Pineal, ageing and telomere-related research | Different sequence and tissue origin |
| Semax | ACTH-derived heptapeptide | Neurotrophic, ischaemia and cognitive research | Longer sequence with different proposed mechanisms |
| Selank | Tuftsin-derived heptapeptide | Anxiety and immune-neural research | Different origin and evidence base |
| Cerebrolysin | Complex porcine-brain peptide preparation | Stroke and dementia clinical research | Mixture rather than one defined tripeptide |
| Cortexin | Animal-cerebral-cortex polypeptide complex | Neurological research and regional clinical use | Complex extract rather than pure EDR |
| DSIP | Nine-amino-acid peptide | Sleep and stress research | Sleep-related name does not create equivalence |
| ARA-290 | Erythropoietin-surface-inspired 11-residue peptide | Neuropathy and tissue-repair research | Different receptor hypothesis and clinical programme |
How to Assess Pinealon and Peptides UK Evidence Critically
Use this checklist before accepting a chemical, neurological, safety or regulatory claim.
- Is the substance identified as Glu-Asp-Arg?
- Is the sequence order confirmed?
- Is Pinealon distinguished from Epitalon?
- Is it distinguished from Cortexin?
- Are the N- and C-termini specified?
- Was intact molecular mass measured?
- Was tandem-MS sequence evidence provided?
- Was L-amino-acid stereochemistry confirmed?
- Were sequence isomers assessed?
- Was pyroglutamate formation measured?
- Were isoaspartate-related impurities assessed?
- Was net peptide content measured?
- Was the counterion identified?
- Were endotoxin and sterility tested where relevant?
- Does the certificate match the supplied batch?
- Was the experiment biochemical, cellular, animal or human?
- Was the peptide fluorescently labelled?
- Was a cancer-cell line used?
- Was blood–brain-barrier entry measured directly?
- Was the research conducted in human participants?
- Was the trial randomised?
- Was it placebo controlled?
- Was Pinealon used alone?
- Was Vesugen or another treatment also used?
- How many participants completed the study?
- Was cognition measured with a validated instrument?
- Were clinical function and daily living assessed?
- Was follow-up long enough to assess durability?
- Was the study independently replicated?
- Is a cell marker being described as a human benefit?
- Is the commercial name being used to imply pineal action?
- Is gene expression being presented as lifespan extension?
- Is lack of reported toxicity being presented as proof of safety?
- Is the source selling the product it describes?
Medical and Editorial Review
This final article has been reviewed for medical context, evidence presentation, patient safety language and editorial clarity by the multidisciplinary panel below.
The reviewers and contributors are identified to provide clear authorship and accountability. Their inclusion does not represent endorsement of any research product, supplier, personal use, treatment claim or commercial statement discussed in this article.
Dr Laura Geige
Medical Director and Senior Aesthetics Practitioner at It’s Me & You Clinic, with a background in dentistry, medical aesthetics and cosmetic dermatology.
Read professional profile
Dr Rimas Geiga
Medical doctor with a special interest in nutritional sciences, dietology, metabolic health and evidence based preventative care.
Read professional profile
Dr Snieguole Geige
Dentist and medical doctor with experience across healthcare, preventative medicine and patient centred clinical standards.
Read professional profile
Dr Giedre Narkiene
Medical doctor and board certified dermatologist with expertise in medical and cosmetic dermatology, skin health and patient safety.
Read professional profile
Dr Veronika Matutyte
Medical doctor with training and professional experience in gerontology and healthcare management across clinical and hospital settings.
Read professional profile
Livija Samušienė
Qualified cosmetologist with a Bachelor of Health Sciences in cosmetology and a professional interest in skin health, acne and evidence based aesthetic care.
Read professional profilePinealon Peptide UK Frequently Asked Questions
Evidence-led answers about EDR chemistry, brain research, safety, testing and UK regulation.
What is Pinealon?
Pinealon is a synthetic tripeptide containing glutamic acid, aspartic acid and arginine.
What is the Pinealon amino-acid sequence?
Its sequence is Glu-Asp-Arg, abbreviated EDR.
How many amino acids does Pinealon contain?
It contains three amino-acid residues and is therefore classified as a tripeptide.
What is Pinealon’s molecular weight?
The free peptide has an approximate average molecular weight of 418.4 g/mol.
Is Pinealon the same as EDR peptide?
Yes. EDR is the single-letter abbreviation for the Glu-Asp-Arg sequence commonly called Pinealon.
Is Pinealon the same as Epitalon?
No. Pinealon is EDR, while Epitalon is the four-amino-acid AEDG peptide.
Is Pinealon derived from the pineal gland?
Research literature associates EDR with cerebral-cortex peptide complexes. The commercial name should not be treated as proof of pineal-gland specificity.
Is Pinealon part of Cortexin?
EDR has been described as a short sequence associated with cerebral-cortex polypeptide complexes. Cortexin itself is a complex mixture and is not identical to purified synthetic Pinealon.
Does Pinealon cross the blood–brain barrier?
Direct human blood–brain-barrier penetration has not been established. Labelled-peptide uptake in cultured cells does not answer this question.
Can Pinealon enter cell nuclei?
Fluorescence-labelled Pinealon was observed in the nuclei of cultured HeLa cells. The label and cell model limit translation to unlabelled peptide in people.
Does Pinealon bind to DNA?
Biophysical studies reported interactions with selected DNA oligonucleotides in vitro. Human genomic target engagement has not been established.
How is Pinealon proposed to work?
Proposed mechanisms include oxidative-stress modulation, altered MAPK signalling, apoptosis-related protein changes, gene-expression effects and support for neuronal processes.
Is Pinealon an antioxidant?
Cell studies reported reduced reactive oxygen species. A small human study involving Pinealon and Vesugen also reported pro-oxidant measurements, so the effect should not be described as universally antioxidant.
Does Pinealon improve memory?
Animal studies and small human reports provide preliminary signals. Robust independent human evidence establishing meaningful memory improvement is lacking.
Does Pinealon prevent Alzheimer’s disease?
No. Laboratory research has examined Alzheimer’s-related pathways, but clinical prevention has not been demonstrated.
Can Pinealon reverse dementia?
No large controlled clinical trial has established reversal of dementia or restoration of independent function.
Does Pinealon regenerate neurons?
Cultured-neuron studies reported increased dendritic arborisation and selected spine changes. Clinical regeneration of functional human neurons has not been established.
Has Pinealon been studied in human neurons?
A 2024 study used induced neurons created from fibroblasts donated by older adults. It remained a laboratory cell study rather than treatment of participants.
Does Pinealon increase serotonin?
Serotonin-expression changes were reported in ageing rat cortical-cell cultures. Human brain serotonin changes have not been established.
Does Pinealon treat depression or anxiety?
No adequate randomised clinical trial has established Pinealon as a treatment for depression or anxiety.
Does Pinealon improve sleep?
Robust clinical evidence involving polysomnography or validated insomnia outcomes was not identified.
Does Pinealon increase melatonin?
A reliable controlled human melatonin-secretion effect has not been established.
Does Pinealon extend telomeres?
No controlled human study has established Pinealon-induced telomere extension.
Does Pinealon extend lifespan?
No human survival trial has demonstrated longer lifespan from Pinealon.
What human Pinealon studies exist?
Small studies and reviews describe use in older adults, people with organic brain syndromes and occupational groups. Many involved combined treatments and lacked modern trial detail.
Is Pinealon safe?
Long-term human safety has not been established. Existing studies are too small to define uncommon, delayed or population-specific risks.
Can Pinealon affect the cell cycle?
Cell-culture research reported cell-cycle changes at selected concentrations. The clinical significance is unknown.
Is Pinealon safe during pregnancy?
Adequate pregnancy, breastfeeding and developmental safety evidence has not been established.
Is Pinealon approved in the UK?
No current UK marketing authorisation was identified.
Does “Research Use Only” settle its UK legal status?
No. The MHRA may consider pharmacological action, intended purpose, claims, imagery, instructions and the complete commercial presentation.
Is Pinealon prohibited in competitive sport?
It was not identified by name on the reviewed 2026 WADA list. As an unapproved pharmacologically active substance, the general S0 category may be relevant and athletes require an official ruling.
Does 99% HPLC prove a product is Pinealon?
No. Sequence isomers can share the same formula and molecular mass. Tandem-MS sequencing, stereochemical analysis and terminal confirmation are required.
What should a Pinealon certificate include?
It should include intact mass, Glu-Asp-Arg sequence confirmation, stereochemistry, terminal structure, assay, impurity profile, counterions and batch-specific quality results.
Does this article provide Pinealon dosing instructions?
No. It does not provide sourcing, preparation, reconstitution, injection, oral use, dose selection, cycling, stacking or self-experimentation guidance.
Key Takeaways
- Pinealon is the Glu-Asp-Arg tripeptide.
- Its single-letter abbreviation is EDR.
- It contains three standard L-amino acids.
- Its approximate molecular weight is 418.4 g/mol.
- It has free N- and C-terminal groups.
- It contains no disulphide bonds.
- Pinealon is not Epitalon.
- Its name does not prove pineal-gland specificity.
- Most evidence comes from cell and animal studies.
- Labelled Pinealon entered cultured HeLa cells and nuclei.
- This does not prove human blood–brain-barrier penetration.
- In-vitro DNA interactions have been reported.
- Selective human genomic regulation has not been established.
- Cell studies reported oxidative-stress and survival effects.
- A 2024 induced-neuron study reported greater dendritic arborisation.
- The same study did not improve every cellular-ageing marker.
- Animal studies examined hypoxia, diabetes and learning.
- Serotonin-expression evidence came from cultured rat cells.
- No clinical Alzheimer’s treatment effect has been established.
- No robust sleep or melatonin benefit has been established.
- No human lifespan extension has been demonstrated.
- Human studies are small and often use combined interventions.
- One small human study reported pro-oxidant and CD34-related findings.
- No current UK marketing authorisation was identified.
- Sequence isomers can share the same intact mass.
- A high HPLC percentage cannot establish pharmaceutical identity or safety.
Relevant It’s Me & You Clinic Peptides UK Resources
Explore related evidence-led articles and contributor profiles.
Epitalon Peptide UK
Compare Pinealon’s EDR tripeptide with the separate AEDG tetrapeptide used in pineal and ageing research.
Browse related peptide guidesSemax Peptide UK
Review a longer ACTH-derived peptide investigated in neurological and neurotrophic research.
Browse related peptide guidesCerebrolysin Peptide UK
Compare a defined tripeptide with a complex animal-brain-derived peptide preparation.
Browse related peptide guidesResearch Peptides UK
Browse the wider educational series on peptide identity, evidence, analytical testing and UK regulation.
Browse the Peptides UK education libraryReferences
- PubChem. Glu-Asp-Arg, compound CID 10273502. PubChem chemical record
- ChEBI. Glu-Asp-Arg, CHEBI:156374. ChEBI chemical record
- Khavinson V, et al. EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer’s Disease. Molecules. 2020;26:159. PubMed record
- Kraskovskaya N, et al. Short Peptides Protect Fibroblast-Derived Induced Neurons from Age-Related Changes. International Journal of Molecular Sciences. 2024;25:11363. PubMed record
- Khavinson V, et al. Pinealon increases cell viability by suppression of free radical levels and activating proliferative processes. Rejuvenation Research. 2011;14:535–541. PubMed record
- Fedoreyeva LI, et al. Penetration of short fluorescence-labelled peptides into the nucleus in HeLa cells and in-vitro specific interaction with deoxyribooligonucleotides and DNA. PubMed record
- Silanteva IA, et al. The role of monovalent and divalent ions in peptide Glu-Asp-Arg–DNA interaction. PubMed record
- Kraskovskaya NA, et al. Tripeptides restore the number of neuronal spines under conditions of in-vitro-modelled Alzheimer’s disease. Bulletin of Experimental Biology and Medicine. 2017. Springer article
- Arutjunyan A, et al. Pinealon protects the rat offspring from prenatal hyperhomocysteinaemia. International Journal of Clinical and Experimental Medicine. 2012;5:179–185. Full article
- Kozina LS. Investigation of antihypoxic properties of short peptides. Advances in Gerontology. 2008;21:61–67. PubMed record
- Karantysh GV, et al. Effect of Pinealon on Learning and Expression of NMDA Receptor Subunit Genes in the Hippocampus of Rats with Experimental Diabetes. Neurochemical Journal. 2020;14:314–320. Springer article
- Khavinson V, et al. Short peptides stimulate serotonin expression in cells of brain cortex. Bulletin of Experimental Biology and Medicine. 2014;157:77–80. PubMed record
- Khavinson V, et al. Short peptides and telomere-length regulator hormone irisin. Bulletin of Experimental Biology and Medicine. 2016. PubMed record
- Meshchaninov VN, et al. Effect of synthetic peptides on ageing of patients with chronic polymorbidity and organic brain syndrome of the central nervous system in remission. Advances in Gerontology. 2015;28:62–67. PubMed record
- Bashkireva AS, Artamonova VG. The peptide correction of neurotic disorders among professional lorry drivers. Advances in Gerontology. 2012;25:718–728. PubMed record
- Umnov RS, Lin’kova NS, Khavinson VKh. Neuroprotective effects of peptide bioregulators in people of various age. Advances in Gerontology. 2013;26:671–678. PubMed record
- Medicines and Healthcare products Regulatory Agency. MHRA Products database. UK medicinal-product database
- Medicines and Healthcare products Regulatory Agency. Borderline products: how to tell if your product is a medicine. Updated 2 July 2026. MHRA borderline guidance
- Medicines and Healthcare products Regulatory Agency. Guidance Note 8: A guide to what is a medicinal product. Revised 2026. MHRA Guidance Note 8
- Human Medicines Regulations 2012, Regulation 279. UK medicinal-product advertising restriction
- World Anti-Doping Agency. The 2026 Prohibited List. WADA 2026 Prohibited List
- International Council for Harmonisation. ICH Q2(R2): Validation of Analytical Procedures. ICH analytical guideline
- UK Accreditation Service. Laboratory accreditation and ISO/IEC 17025. UKAS laboratory guidance
